Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease regarded as insulin resistance and progressive failure of β cells. Beta cells secretagogues are useful to reach satisfactory glycemic control. Glimepiride is a second-generation sulfonylurea excites pancreatic beta cells to discharge insulin. Glimepiride may be safer to use in patients with cardiovascular disease due to lack of destructive effects on ischemic preconditioning. It is effective in dropping fasting plasma glucose (FPG), postprandial glucose and glycated hemoglobin levels and is a useful and cost-effective option treatment for the management of T2D. Total 40 patients were selected from OPD setting at RSNPMTS Endocrinology center Ministry of Health Republic of Uzbekistan, and corresponding to criteria for inclusion / exclusion. 10 patients with T2D switched from receiving other forms of Glimepiride (Amaryl) on an identical dose of GlucoNovax in combination with biguanides (Metformin) denoted as group 1. At the same time the dose of biguanides (Metformin) was not altered for the period of the study. 10 patients with T2D switched from receiving other forms of Glimepiride (Amaryl) on an identical dose of GlucoNovax denoted as group 2.10 patients with T2D switched to the drug GlucoNovax from the drug Glibenclamide denoted as group 3. The control group received monotherapy with Amaryl it consist of 10 patients with T2D denoted as group 4. The severity of diabetic complaints in patients receiving the combination drug GlucoNovax with metformin significantly decreased by the end of the observation period and had an inclination to reduction in the 2nd and 3rd groups, along with the control group. 30 patients, receiving the drug Gluco Novax, 7 achieved blood glucose level parameters that corresponding to the high effectiveness of the drug (4 of them from 1st group (GlucoNovax+ Metformin), 1 in the 2nd group, 2 in the 3rd group). 6 patients achieved blood glucose levels parameters, meeting the criteria of moderate effectiveness of the drug (4 of them from 1st group, 1 patient in the 2nd and 1 patient in the 3rd groups). The given result may be, associated with initially high levels of compensation of carbohydrate metabolism, as well as a more effective influence on combination treatment with Metformin. The drug GlucoNovax appears to be an effective hypoglycemic agent in the treatment of T2D with good tolerability.